Search research articles
Contact Us
Filters
Showing results (151-160 of 185) with videos related to
Page
of 19
Sort By:
The Oncologist
|
October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
Rodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Journal of Translational Medicine
|
July 1, 2021
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)
Paolo A Ascierto, Christian Blank, Reinhard Dummer, et al.
Annals of Surgical Oncology
|
February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Charles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Corey C Foster, Gini F Fleming, Theodore G Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2020
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial
Jason J Luke, Benjamin E Onderdonk, Sandeep R Bhave, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Muhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Cancer Discovery
|
June 10, 2018
An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors
Tao Wang, Rong Lu, Payal Kapur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
Journal for Immunotherapy of Cancer
|
October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 185) with videos related to
Sort By:
Page
of 19
The Oncologist
|
October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
Rodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Journal of Translational Medicine
|
July 1, 2021
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)
Paolo A Ascierto, Christian Blank, Reinhard Dummer, et al.
Annals of Surgical Oncology
|
February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Charles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Corey C Foster, Gini F Fleming, Theodore G Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2020
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial
Jason J Luke, Benjamin E Onderdonk, Sandeep R Bhave, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Muhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Cancer Discovery
|
June 10, 2018
An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors
Tao Wang, Rong Lu, Payal Kapur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
Journal for Immunotherapy of Cancer
|
October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
Page
of 19